We are live on ! Find out more
FFM

Fairmount Funds Management Portfolio holdings

AUM $1.38B
1-Year Est. Return 407.79%
This Fund
S&P 500
This Quarter Est. Return
-5.87%
1 Year Est. Return
+407.79%
3 Year Est. Return
+2,937.62%
5 Year Est. Return
+5,415.3%
10 Year Est. Return
–
AUM
$423M
AUM Growth
+$120M
Cap. Flow
+$137M
Cap. Flow %
32.5%
Top 10 Hldgs %
74.09%
Holding
23
New
3
Increased
12
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$23.4M
2
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$22.9M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$17.9M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$15.5M
5
INSM icon
Insmed
INSM
+$14.8M

Top Sells

Rank Stock Value
1
ZGNX
Zogenix, Inc.
ZGNX
+$40.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
1
Insmed
INSM
$22.9B
$45.8M 10.83%
1,948,784
+635,177
+48% +$14.8M
GBT
2
DELISTED
Global Blood Therapeutics, Inc.
GBT
$41M 9.68%
1,182,307
+439,307
+59% +$13.1M
ARGX icon
3
argenx
ARGX
$56.1B
$39.2M 9.26%
124,244
+45,600
+58% +$13.3M
AXSM icon
4
Axsome Therapeutics
AXSM
$12.3B
$39M 9.22%
942,571
+754,973
+402% +$23.4M
ENTA icon
5
Enanta Pharmaceuticals
ENTA
$375M
$33.4M 7.9%
469,264
+81,864
+21% +$5.33M
BHVN
6
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$28.4M 6.71%
239,314
+183,667
+330% +$22.9M
ACAD icon
7
Acadia Pharmaceuticals
ACAD
$4.4B
$28M 6.62%
1,156,817
+740,000
+178% +$17.9M
KROS icon
8
Keros Therapeutics
KROS
$205M
$21.6M 5.1%
396,911
+104,078
+36% +$5.34M
NUVL
9
DELISTED
Nuvalent
NUVL
$18.6M 4.4%
1,338,393
+423,779
+46% +$6.16M
PNT
10
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$18.4M 4.36%
2,312,523
+793,141
+52% +$5.04M
VRDN icon
11
Viridian Therapeutics
VRDN
$2.2B
$17.5M 4.13%
944,092
– –
TYRA icon
12
Tyra Biosciences
TYRA
$1.89B
$13.7M 3.25%
1,284,990
+639,641
+99% +$7.59M
AMRN
13
Amarin Corp
AMRN
$286M
$13.6M 3.22%
206,662
+81,750
+65% +$5.39M
PTGX icon
14
Protagonist Therapeutics
PTGX
$8.74B
$13M 3.08%
+549,988
New +$15.5M
COGT icon
15
Cogent Biosciences
COGT
$6.91B
$11.7M 2.76%
1,558,975
– –
OLMA icon
16
Olema Pharmaceuticals
OLMA
$1.08B
$11.4M 2.69%
+2,669,300
New +$14.7M
TIL icon
17
Instil Bio
TIL
$48.4M
$7.24M 1.71%
33,695
– –
IOVA icon
18
Iovance Biotherapeutics
IOVA
$2.2B
$6.49M 1.53%
389,588
– –
ATXS
19
DELISTED
Astria Therapeutics
ATXS
$6.12M 1.45%
911,736
– –
VRNA
20
DELISTED
Verona Pharma
VRNA
$4.62M 1.09%
926,602
– –
ANNX icon
21
Annexon
ANNX
$875M
$3.41M 0.81%
+1,249,143
New +$7.69M
ALLK
22
DELISTED
Allakos
ALLK
$838K 0.2%
147,189
– –
ZGNX
23
DELISTED
Zogenix, Inc.
ZGNX
– –
-2,502,259
Closed -$40.7M

Similar funds

NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
AU
Algebris (UK) London, United Kingdom $1.38B AUM 3.87% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
VC
Vestor Capital Chicago, Illinois $1.38B AUM 39.2% 1-Year Est. Return
AO
Advisor OS Chicago, Illinois $1.38B AUM 16.6% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
OCM
Opti Capital Management New York $1.39B AUM 0% 1-Year Est. Return

Fairmount Funds Management's Q1 2022 Portfolio in Review

As of Q1 2022, Fairmount Funds Management held 23 positions worth $423M, up 39% from $303M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Fairmount Funds Management deployed $137M of net new capital in Q1 2022, opening 3 new positions and adding to 12 existing holdings. Its largest new stake was Protagonist Therapeutics: 549,988 shares worth $13M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the most notable exit was Zogenix, Inc., an estimated $40.7M sold.

  • Fairmount Funds Management's largest Q1 2022 buy was Protagonist Therapeutics: 549,988 shares worth $13M.
  • Fairmount Funds Management added most to Axsome Therapeutics in Q1 2022, an estimated $23.4M increase.
  • Fairmount Funds Management fully exited Zogenix, Inc. in Q1 2022, selling an estimated $40.7M.
  • Fairmount Funds Management's ten largest holdings make up 74% of its $423M portfolio in Q1 2022.
  • Fairmount Funds Management opened 3 new positions and closed 1 in Q1 2022.
  • Fairmount Funds Management's portfolio value rose 39% quarter-over-quarter to $423M.

Based on Fairmount Funds Management's 13F filing for Q1 2022, filed 16 May 2022.